83.10 +0.43 (0.52%)
After hours: 7:36PM EDT
Commodity Channel Index
|Bid||82.64 x 800|
|Ask||82.65 x 1800|
|Day's Range||81.79 - 85.44|
|52 Week Range||55.90 - 112.22|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.67|
The public offering was increased from the previously announced offering size of 10,000,000 shares of common stock. In addition, Guardant Health and SoftBank Investment Advisers have granted the underwriter a 30-day option to purchase up to 1,725,000 additional shares of common stock (562,500 additional shares from Guardant Health and 1,162,500 additional shares from SoftBank Investment Advisers) at the public offering price, less underwriting discounts and commissions.
In addition, Guardant Health and SoftBank Investment Advisers expect to grant the underwriter a 30-day option to purchase up to 1,500,000 additional shares of common stock (450,000 additional shares from Guardant Health and 1,050,000 additional shares from SoftBank Investment Advisers) at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
REDWOOD CITY, Calif., May 29, 2020 -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming William Blair Virtual Growth Stock.
There are a few fantastic growth stocks that you can buy right now that have a good shot at making you a lot of money relatively quickly. David Gardner, co-founder of The Motley Fool, thinks that investors should "make your portfolio reflect your best vision for our future." One really positive vision for the future is a world where most cases of cancer can be detected early enough to be successfully treated.
REDWOOD CITY, Calif., May 15, 2020 -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting.
Ladies and gentlemen, thank you for standing by, and welcome to the Guardant Health Q1 2020 Earnings Call. Earlier today, Guardant Health released financial results for the quarter ended March 31, 2020.
Guardant Health posted a strong first-quarter beat, sending Guardant Health stock briefly into breakout territory Friday even after the diagnostics company pulled its 2020 outlook.
REDWOOD CITY, Calif., May 07, 2020 -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its.
Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify
REDWOOD CITY, Calif., May 06, 2020 -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming BofA Securities Virtual Healthcare.
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent1 of patients at increased risk of receiving a less effective treatment.
Consider investing it in one of these hot growth stocks and holding your position for at least five years. Alteryx (NYSE: AYX) solves this problem. Users love Alteryx's software so much that it won the 2019 Gartner Peer Insights Customers' Choice award for data science and machine learning platforms.
Guardant Health, Inc. (GH) presents new data at Digestive Disease Week (DDW) 2020 that highlights the performance of its LUNAR-2 assay and reinforces its potential to improve colorectal cancer (CRC) screening rates by offering a simpler blood test that overcomes barriers associated with current testing methods. “Despite the recent challenges of the COVID-19 pandemic, the ability to hold scientific discussions on research of cancer and other diseases, even in a virtual capacity like this year’s DDW, is essential to ensure our collective fight against cancer continues to advance,” said Helmy Eltoukhy, PhD, co-founder and CEO. Abstract #Sa1651 and Poster of Distinction: Plasma based cell-free circulating tumor DNA (ctDNA) assessment for non-invasive detection of colorectal cancer (CRC).
REDWOOD CITY, Calif., April 30, 2020 -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the first quarter 2020 after market close on.
REDWOOD CITY, Calif., April 09, 2020 -- Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
It's been a mediocre week for Guardant Health, Inc. (NASDAQ:GH) shareholders, with the stock dropping 13% to US$75.79...